Abstract
Broncho-obstructive syndrome (BOS) is a frequent complication in lung sarcoidosis, often exacerbated by comorbid conditions such as coronary heart disease (CHD). This study investigates the clinical efficacy of a 30-day combined inhalation therapy (budesonide/formoterol) in managing BOS. Results indicate that targeted inhalation significantly improves respiratory function (FEV1) and allows for a substantial reduction in systemic corticosteroid dosages, mitigating potential cardiovascular side effects.
Introduction
Sarcoidosis is a multisystem inflammatory disease characterized by the formation of non-caseating granulomas, primarily within the lungs. While often viewed as a restrictive lung disease, many patients experience broncho-obstructive syndrome (BOS) during the early stages. The management of BOS becomes particularly challenging in patients with concomitant coronary heart disease (CHD). In these cases, respiratory distress is often a "mixed" phenomenon where pulmonary inflammation and cardiac insufficiency exacerbate one another.
Standard treatment typically involves systemic corticosteroids like prednisone; however, these carry significant risks for CHD patients, including hypertension and fluid retention. This study explores whether inhaled combination therapy can serve as a safer, effective alternative for managing airway narrowing in this high-risk group.
Methodology
The research involved a comparative clinical study of 91 patients diagnosed with lung sarcoidosis at the Central Scientific Research Institute of Tuberculosis in Moscow. The cohort was divided into two groups:
- Main Group (n=43): Patients with both lung sarcoidosis and CHD.
- Comparison Group (n=48): Patients with lung sarcoidosis but no CHD.
All participants received a 30-day course of "Symbicort" (budesonide 320 mcg / formoterol 9 mcg) daily. Diagnostic evaluation included high-resolution CT scans for radiological staging (using the K. Wurm scale), spirometry, body plethysmography to detect "air traps," and DLCO to assess gas exchange. Blood gas analysis and oxygen saturation ($SpO_2$) were also monitored to track physiological improvements.
Results
The intervention yielded significant functional improvements across both groups, with particularly notable gains in the high-risk CHD cohort:
- Lung Function Improvement: In the main group (sarcoidosis + CHD), the Forced Expiratory Volume in 1 second ($FEV_1$) increased from a baseline of 60.33% to 82.43% after 30 days. Bronchial patency was fully normalized in approximately 25% of these patients.
- Symptom Relief: Dyspnea scores in the main group decreased from 1.38 to 1.12, while cough scores dropped from 0.43 to 0.31.
- Steroid Sparing Effect: A critical finding was the ability to reduce systemic corticosteroid intake. Patients with CHD were able to lower their daily prednisone dose from an average of 20 mg to 15 mg (a 1.33 to 1.5-fold reduction), significantly lowering the risk of systemic toxicity.
Discussion
The study highlights that CHD acts as a "symptom multiplier" in sarcoidosis, worsening cough and dyspnea even in early radiological stages. The mechanism of obstruction in these patients is multifactorial, involving inflammatory edema, fibrotic changes, and external compression of the airways by lymphadenopathy. The success of inhaled budesonide/formoterol suggests that localized treatment can effectively manage these "mixed" obstructive components while sparing patients from the systemic toxicity of high-dose oral steroids.
Conclusion and Future Work
Combined inhalation therapy with budesonide and formoterol is an effective strategy for treating broncho-obstructive syndrome in sarcoidosis patients, especially those with cardiovascular comorbidities. By improving airflow and reducing the need for systemic prednisone, this approach offers a safer therapeutic window for complex, multi-morbid patients.
While the 30-day results are promising, the study's relatively small sample size and short duration suggest a need for larger, long-term trials. Future research should investigate whether early initiation of this therapy can prevent the progression of permanent fibrotic changes in the lungs.
Summary updated